Hynes Convention Center

Boston Planning Agency Greenlights Hawkins Way Capital's Sheraton Boston Conversion

Retrieved on: 
Tuesday, January 23, 2024
Entrepreneurship, Prudential Center, Aid, Housing, Hynes Convention Center, Northeastern University, BDPA, Partner (business rank), COVID-19, Hotel

BOSTON, Jan. 23, 2024 /PRNewswire/ -- The Boston Planning and Development Agency (BDPA) has approved Hawkins Way Capital's conversion of the Sheraton Boston Hotel's South tower into student housing.

Key Points: 
  • BOSTON, Jan. 23, 2024 /PRNewswire/ -- The Boston Planning and Development Agency (BDPA) has approved Hawkins Way Capital's conversion of the Sheraton Boston Hotel's South tower into student housing.
  • Acquired by Hawkins Way Capital in 2022, the 1.1 million square foot Sheraton Boston Hotel's South tower was occupied by Northeastern University under temporary order during the COVID-19 pandemic, while the North tower continued to operate as a Sheraton hotel.
  • Ross Walker, Co-Founder and Managing Partner at Hawkins Way Capital, stated, "Our Sheraton Boston Hotel revitalization showcases the natural transformation of a select type of declining urban hotel to stay competitive.
  • In addition, Hawkins Way Capital will commence a substantial capital improvement program planned for the 792-key Sheraton Boston Hotel North tower in order to upgrade the rooms and common areas to the new generation of Sheraton brand standards.

89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, November 8, 2023
FDA, Sale, Hynes Convention Center, Research and development, Ballroom, Food, BTD, Liver, Fibrosis, R, F4, NASH, Safety, Patient, Food and Drug Administration, Administration, SAN, Pharmaceutical industry, Cryptocurrency, G&A

SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN FRANCISCO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the third quarter ended September 30, 2023.
  • “We are making excellent progress in developing pegozafermin as a potential leading treatment for liver and cardiometabolic diseases,” stated Rohan Palekar, CEO of 89bio.
  • Additionally, we are continuing to enroll patients in ENTRUST, the Phase 3 trial of pegozafermin in patients with SHTG.
  • As of September 30, 2023, 89bio had cash, cash equivalents and short-term available-for-sale securities totaling $448.3 million.

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Retrieved on: 
Friday, November 3, 2023
Hepatocyte, Hynes Convention Center, American Association for the Study of Liver Diseases, Therapy, Hepatology, Liver, Pharmacokinetics, Sarcopenia, Safety, GALT, Glomerular filtration rate, GA 2, AM, Abstract (summary), Obesity, Indiana University School of Medicine, Cirrhosis, Data monitoring committee, Disease, Hepatic hydrothorax, Medical school, Indiana University, SC 4, K–Ca dating, Non-alcoholic fatty liver disease, AASLD, Dietary supplement, Pharmaceutical industry, Flour, Patient

NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).
  • The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.
  • “This year again we are happy to share some of the progress we have made in our global program with belapectin, our galectin-3 inhibitor.
  • We are also proud to bring additional knowledge to the field regarding liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long,” said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 6, 2023
Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Sale, Hynes Convention Center, Harvard Medical School, American Association for the Study of Liver Diseases, Food, Therapy, Hepatology, Rocky Vista University College of Osteopathic Medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Doctor of Science, De novo, Ultrasound, Disease, Weill Cornell Medicine, KOL, Diabetes, NDRA, Metabolism, Patient, AASLD, Medical imaging, Radiology, Endocrinology, Medicine

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced it will host an offsite panel discussion with multidisciplinary experts during the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting, taking place November 10-14, 2023, in Boston.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced it will host an offsite panel discussion with multidisciplinary experts during the American Association for the Study of Liver Diseases (AASLD) annual meeting, The Liver Meeting, taking place November 10-14, 2023, in Boston.
  • The panel will feature three key opinion leaders (KOLs) in the fields of hepatology, endocrinology and radiology sharing their unique perspectives on managing Metabolic-Associated Steatotic Liver Disease (MASLD).
  • “We are delighted to be attending the prestigious AASLD The Liver Meeting and contributing to the topical discussion of early detection and management of MASLD.
  • “With the near-term prospect of therapeutics for treating steatotic liver disease coming to market, there is a pressing clinical need for a non-invasive and cost-effective tool to screen and monitor patients,” he added.

SUMMIT CLINICAL RESEARCH (THE LEADING INTEGRATED RESEARCH ORGANIZATION IN THE MASH FIELD) TO PRESENT LEADING EDGE INSIGHTS AT THE AASLD LIVER MEETING FROM OVER 6,000 PATIENTS ACROSS MULTIPLE CLINICAL TRIALS

Retrieved on: 
Monday, October 30, 2023
FDA, NIT, Hynes Convention Center, DSM-IV codes, Physician, Health, Research, AM, Summit, Clinical trial, Steatosis, Atherosclerosis Risk in Communities, Disease, NASH, Fibrosis, SCR, Hepatology, MASH, Audubon Ballroom, Metabolism, SAN, AASLD, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Aluminium, Patient, Non-alcoholic fatty liver disease, Medicine

The research, focusing on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related subjects contains significant findings derived from therapeutic trials involving over 6,000 patients.

Key Points: 
  • The research, focusing on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related subjects contains significant findings derived from therapeutic trials involving over 6,000 patients.
  • Dr. Harrison, Founder and Chairman of Summit Clinical Research; Founder and Chairman of Pinnacle Clinical Research, commented: "Summit Clinical Research is a beacon in the MASH arena.
  • The presentations at the AASLD Liver Meeting highlight the critical role of continued research in liver diseases and metabolic disorders.
  • Summit Clinical Research is honored to significantly contribute to these efforts and share our insights with the medical community.

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Wednesday, October 4, 2023
Toxicity, Carcinoma, AACR, Diabetes, Clinical trial, Cancer, Pulmonary toxicity, TUSC2, Research, NSCLC, Treatment of lung cancer, Lung cancer, Hynes Convention Center station, Fast track (FDA), SCLC, Patient, Hynes Convention Center, Therapy, Conference, Disease, Pharmaceutical industry

AUSTIN, Texas, Oct. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that research collaborators will present positive clinical and preclinical data from studies of its lead product candidate, REQORSA® (quaratusugene ozeplasmid) used for the treatment of lung cancers, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place from October 11-15, 2023 at the Hynes Convention Center in Boston. REQORSA is a non-viral gene therapy that leads to expression of the TUSC2 tumor suppressor gene in cancers.

Key Points: 
  • REQORSA is a non-viral gene therapy that leads to expression of the TUSC2 tumor suppressor gene in cancers.
  • "The encouraging Phase 1 results in the Acclaim-1 trial document REQORSA's favorable safety profile thus far and show early efficacy in patients with non-small cell lung cancer (NSCLC) whose disease has progressed on Tagrisso.
  • "In addition, the preclinical data presented by our research collaborators is very encouraging, as we know that despite the broader success of immunotherapies, such as checkpoint inhibitors, they have limited efficacy in the treatment of small cell lung cancer.
  • Details of the presentations are outlined below:
    "Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and osimertinib"

Largest International Assembly on Chronic Lymphocytic Leukemia (CLL) Raises Curtain on 20th Biennial Meeting in Boston, Massachusetts

Retrieved on: 
Tuesday, October 3, 2023
CLL, International Workshop on Lung Health, Abstract, Partnership, Lymphoproliferative disorders, Epidemiology, Court of general sessions, Research, Genomics, Doctor of Philosophy, BTK, Proteomics, Hynes Convention Center, Harvard Medical School, Medicine, Metabolism, MD, Patient, Physician, Hematology, XX, Diagnosis, Chronic lymphocytic leukemia, Leukemia, Health, Social media, Disease, Dana–Farber Cancer Institute, Medical device, Veterinary medicine

BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts. Founded in 1979, iwCLL is the world's leading member-driven organization dedicated to the field of CLL and related lymphoproliferative disorders, bringing together leaders from scientific research, clinical medicine, and the pharmaceutical and biotechnology industries.

Key Points: 
  • BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts.
  • The International Workshop on Chronic Lymphocytic Leukemia hosts its 20th biennial meeting in Boston on Oct. 6-9, 2023.
  • "Recent data from both the laboratory and clinic have reignited the CLL community's enthusiasm and dedication toward finding a cure.
  • The 4-day event will begin on Friday with a Young Investigator Meeting, applicable for individuals early in their hematology careers.

Vector BioMed's CEO, Dr. Boro Dropulić, to Speak at the 8th CAR-TCR Summit

Retrieved on: 
Monday, August 21, 2023
BioMed Central, Hynes Convention Center station, GMP, Hynes Convention Center, Concept, The Car, Vaccine

GAITHERSBURG, Md., Aug. 21, 2023 /PRNewswire/ -- Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today, announced that Dr. Boro Dropulić, CEO, will speak at the 8th CAR-TCR Summit taking place at the Hynes Convention Center in Boston, MA from August 29-September 1, 2023.

Key Points: 
  • Details of the presentation are as follows:
    A Rapid & Affordable Lentiviral Vector Manufacturing Platform: From
    Concept to Clinic Within 12 Months.
  • Dr. Dropulić said "The CAR-TCR Summit brings together many important stakeholders to discuss the latest advances in the field.
  • Vector BioMed is positioned to capitalize on this significant market need with its superior lentiviral vector manufacturing platform that reliably produces high-titer lentiviral vectors.
  • The high titer reduces the cost of production, which Vector BioMed passes on to its partners.

CyberArk to Host Investor Track at IMPACT 23: The Identity Security Conference

Retrieved on: 
Thursday, May 18, 2023
Data Management, Security, Technology, Software, Networks, Internet, CYBR, Hynes Convention Center, Webcast, IMPACT, Keynote, Nightclub, Cryptocurrency, CyberArk, Levels of identity security

CyberArk (NASDAQ: CYBR ), the global leader in Identity Security , today announced that it will host an Investor Track during CyberArk IMPACT 23 , the company’s annual conference dedicated to strategies and technologies for defending against identity-based cyberattacks.

Key Points: 
  • CyberArk (NASDAQ: CYBR ), the global leader in Identity Security , today announced that it will host an Investor Track during CyberArk IMPACT 23 , the company’s annual conference dedicated to strategies and technologies for defending against identity-based cyberattacks.
  • Members of CyberArk’s executive team will discuss our leadership position in Identity Security, our innovation roadmap, as well as market dynamics and our go-to-market approach.
  • The Investor Track will take place at the Hynes Convention Center in Boston on May 23 beginning at 1:30 p.m. Eastern Time.
  • The Investor Track will be webcast live via the “Investor Relations” section of the company’s website at www.cyberark.com .

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Retrieved on: 
Monday, May 15, 2023
Immortalised cell line, PEGS, Omicron, Probability, Therapy, G protein-coupled receptor, COVID-19, Research, Operation (mathematics), Antibody, Immunotherapy, Hynes Convention Center station, Discovery, CELL, Cell, Protein engineering, Hynes Convention Center, Eurosport 1, Fine chemical, Vaccine, Beacon

EMERYVILLE, Calif., May 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery.

Key Points: 
  • Affordable two-chip Beacon Select system to broaden customer access to innovative high throughput, function-first antibody discovery capabilities
    EMERYVILLE, Calif., May 15, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Beacon Select™ optofluidic system with Opto® B Discovery workflows for antibody discovery .
  • Combined with the value-matched Beacon Select system, more customers may access these propriety antibody discovery applications, but with the optimum level of features that meet their research and budgetary needs.
  • Opto B Discovery workflows on the Beacon Select system enable scientists to accelerate antibody screening and hit generation to find lead candidate antibodies and are ideally suited for small- to mid-sized biopharma and CDMOs/CROs.
  • To further increase customer accessibility and affordability, PhenomeX will offer the Beacon Select system for antibody discovery with different purchase options including capital placement, lease, or reagent rental.